Marie Christin Hasselluhn
Has grant
Associate Research Scientist
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Combination CAF/myeloid targeting for pancreatic cancer therapy
Open Date: 2020-01-01
Close Date:
Articles (35)
Year:
2025
Pancreatic ductal adenocarcinoma is a deadly disease and is projected to become the second leading cause of cancer-related death by 2030. A major hallmark is the exuberant host response comprising the tumor microenvironment, of which, cancer-associated fibroblasts (CAF) are a prevalent component. Despite the gains in understanding of their heterogeneity and functionality from CAF studies in recent years, there are many unanswered questions surrounding this diverse population of cells. Here, we summarize the views of several experts in the field, focusing on the current understanding of CAFs and challenges to address.
Year:
2024
Year:
2024
Pancreatic ductal adenocarcinoma (PDAC) poses significant challenges for effective treatment, with systemic chemotherapy often proving inadequate due to poor drug delivery and the tumor’s immunosuppressive microenvironment. Engineered bacteria present a novel approach to target PDAC, leveraging their ability to colonize tumors and deliver therapeutic payloads. Here, we engineered probiotic Escherichia coli Nissle 1917 (EcN) to produce the pore-forming Theta toxin (Nis-Theta) and evaluated its efficacy in a preclinical model of PDAC. Probiotic administration resulted in selective colonization of tumor tissue, leading to improved overall survival compared to standard chemotherapy. Moreover, this strain exhibited cytotoxic effects on both primary and distant tumor lesions while sparing normal tissues. Importantly, treatment also modulated the tumor microenvironment by increasing anti-tumor immune cell populations and reducing immunosuppressive markers. These findings demonstrate the potential of engineered probiotic bacteria as a safe and effective therapeutic approach for PDAC, offering promise for improved patient outcomes.
Year:
2024
Epithelial network. Regulatory network for PDAC-associated epithelial cells, listing the inferred transcriptional targets (Target) for each regulatory protein (Regulator). Association weight (AW) and association mode (AM) are scores to quantify strength/direction of interaction. Sign indicates directionality of the interaction (1 = transactivating, -1 = transrepressing).
Year:
2024
Endothelial network. Regulatory network for PDAC-associated endothelial cells, listing the inferred transcriptional targets (Target) for each regulatory protein (Regulator). Association weight (AW) and association mode (AM) are scores to quantify strength/direction of interaction. Sign indicates directionality of the interaction (1 = transactivating, -1 = transrepressing).
Year:
2024
Supplementary Table 1: Raw read counts per gene for bulk RNA-seq IPI-926 intervention study. Raw read counts of matching biopsy (Bx) and necropsy (Nx) bulk RNA-seq samples after two days of treatment with vehicle or IPI-926. Supplementary Table 2: Digestion buffer for single cell preparation. List of reagents optimized for single cell digestion of KPC-derived tumors. Supplementary Table 3: Single Cell RNA-seq Quality Control. Overview of KPC-derived scRNA-seq samples, containing treatment information (vehicle or IPI-926; n=3 each), sequencing depth, detected genes, and detection of mitochondrial genes (MT%). Supplementary Table 4: Network sizes in murine scRNA-seq data. Number of regulatory proteins for which regulons were generated in each network type, in each cell type, from KPC mouse pancreatic tumors.
Year:
2024
Myeloid network. Regulatory network for PDAC-associated myeloid cells, listing the inferred transcriptional targets (Target) for each regulatory protein (Regulator). Association weight (AW) and association mode (AM) are scores to quantify strength/direction of interaction. Sign indicates directionality of the interaction (1 = transactivating, -1 = transrepressing).
Year:
2024
Lymphoid network. Regulatory network for PDAC-associated lymphoid cells, listing the inferred transcriptional targets (Target) for each regulatory protein (Regulator). Association weight (AW) and association mode (AM) are scores to quantify strength/direction of interaction. Sign indicates directionality of the interaction (1 = transactivating, -1 = transrepressing).
Year:
2024
Myeloid network. Regulatory network for PDAC-associated myeloid cells, listing the inferred transcriptional targets (Target) for each regulatory protein (Regulator). Association weight (AW) and association mode (AM) are scores to quantify strength/direction of interaction. Sign indicates directionality of the interaction (1 = transactivating, -1 = transrepressing).
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (7)
Hanina Hibshoosh
Professor of pathology at CUIMC
Columbia University
Tal Danino
Columbia University
Alexander Muir
Assistant professor
University of Chicago
Débora Barbosa Vendramini-Costa
Associate Professor Research
Michigan State University
Kenneth Olive
Assistant Dean of Graduate Curricula and Associate Professor of Medicine
Columbia University Irving Medical Center
Andrea Califano
Columbia University Irving Medical Center
Tetsuhiro Harimoto
Dana-Farber Cancer Institute
Make your next move.
Prepare your application
Review drafts before you send them.